Beam Therapeutics Inc. (BEAM) insider trading

By person

14 insiders · 252 transactions

42.9×

John Evans holds 42.9 times base salary in stock. $32.45M of shares against $755.00K in salary for 2025.

Salary from the company's own proxy. The shares are what John Evans last reported holding, valued at $23.98, the price Common Stock was last bought or sold at on the open market here, on 16 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Fmr LLC entity

10% owner

—

$40.83M (15)

−$40.83M

7,212,606

6.98%

$172.99M

+34.7%

John M. Evans

CEO

—

$36.48M (93) scheduled

−$36.48M

1,253,205

1.21%

$30.06M

+2.4%

Giuseppe Ciaramella

President

—

$28.64M (43) scheduled

−$28.64M

253,911

0.2458%

$6.09M

+105.8%

Terry-Ann Burrell

Chief Financial Officer

—

$15.69M (25) scheduled

−$15.69M

82,637

0.0800%

$1.98M

+4,011%

Amy Simon

Chief Medical Officer

—

$2.50M (16) scheduled

−$2.50M

85,696

0.0830%

$2.06M

+28.1%

Christine Bellon

Chief Legal Officer

—

$1.90M (18) scheduled

−$1.90M

109,711

0.1062%

$2.63M

+87.7%

Graham K Cooper

Director

—

$1.60M (17) scheduled

−$1.60M

0.0000%

$0.00

—

Bethany J Cavanagh

SVP, Finance and Treasurer

—

$713.75K (9) scheduled

−$713.75K

50,984

0.0494%

$1.22M

+20.5%

Sravan Kumar Emany

Chief Financial Officer

—

$170.57K (1) scheduled

−$170.57K

105,456

0.1021%

$2.53M

—

Robert Nelsen

Director

—

3,535,572

3.42%

$84.80M

—

ARCH Venture Partners IX, LLC entity

10% owner

—

2,949,630

2.86%

$70.74M

—

Kristina Burow

Director

—

2,933,586

2.84%

$70.36M

—

Redmile Group, LLC entity

10% owner

—

1,161,458

1.12%

$27.86M

—

Mark Fishman

Director

—

17,007

0.0165%

$407.89K

—

Beam Therapeutics Inc.

What the insiders did Net selling

By person